Educational content on VJOncology is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

The Lung Cancer Channel is supported with funding from Johnson & Johnson (Gold) and Iovance Biotherapeutics (Silver).

The Skin Cancer Channel is supported with funding from Iovance Biotherapeutics (Silver).

VJOncology is an independent medical education platform. Supporters, including channel supporters, have no influence over the production of content. The levels of sponsorship listed are reflective of the amount of funding given to support the channel.

Share this video  

ASCO 2025 | Utilizing midkines to improve outcomes in SCLC and MCC

Curtis Perry, MD, PhD, Yale University, New Haven, CT, describes the benefits of identifying midkines in immune resistant Merkel cell carcinoma (MCC) and small cell lung cancer (SCLC) tumors, highlighting the possibility of improved patient outcomes through enhanced treatment strategies. Dr Perry emphasizes the importance of personalized medicine and the need for further research to fully understand the mechanisms underlying these cancers. This interview took place during the 2025 American Society of Clinical Oncology (ASCO) Meeting in Chicago, IL.

These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.

Transcript

We’re really hopeful that both midkines specifically, but also most likely many other different therapies and interventions are going to be required to deal with patients whose tumors find a way to be resistant to immunotherapy. So we really want to be able to use not only midkines but also this platform to really be able to study novel therapies as we continue to advance and really try to be able to bring therapies forward more efficiently, safer to patients who need them...

We’re really hopeful that both midkines specifically, but also most likely many other different therapies and interventions are going to be required to deal with patients whose tumors find a way to be resistant to immunotherapy. So we really want to be able to use not only midkines but also this platform to really be able to study novel therapies as we continue to advance and really try to be able to bring therapies forward more efficiently, safer to patients who need them. Thank you.

This transcript is AI-generated. While we strive for accuracy, please verify this copy with the video.

Read more...

Disclosures

Research Funding – AstraZeneca (Inst)

Choose your cookie settings

VJOncology uses necessary cookies to make the site work. With your permission we'd also like to use analytics, preference and marketing cookies to understand how the site is used and improve it.

Choose an option to continue. You can change it at any time on our Cookie Policy page, linked at the bottom of every page.